Claims for Patent: 11,559,535

« Back to Dashboard

Summary for Patent: 11,559,535

Title:	Concentrated liquid pharmaceutical formulations of furosemide
Abstract:	Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.
Inventor(s):	Alfredo Grossi, Britt Kostraba, Olatokumbo O. Luca Ogunleye, Shannon Terry, Franciscus KOPPENHAGEN
Assignee:	ScPharmaceuticals Inc
Application Number:	US17/817,731
Patent Claims:	1. A liquid pharmaceutical formulation comprising: furosemide, or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide is from about 60 mg/mL to about 150 mg/mL; benzyl alcohol, wherein the amount of benzyl alcohol is from about 0.1% (w/w) to about 10% (w/w); and a pharmaceutically acceptable buffer comprising tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of tromethamine is from about 25 mM to about 150 mM; wherein the liquid pharmaceutical formulation has a pH of between about 6.5 to about 8.5. 2. The liquid pharmaceutical formulation of claim 1, wherein the concentration of furosemide is from about 60 mg/mL to about 120 mg/mL. 3. The liquid pharmaceutical formulation of claim 1, wherein the concentration of furosemide is from about 70 mg/mL to about 90 mg/mL. 4. The liquid pharmaceutical formulation of claim 1, wherein the amount of benzyl alcohol is from about 0.5% (w/w) to about 5% (w/w). 5. The liquid pharmaceutical formulation of claim 1, wherein the amount of benzyl alcohol is from about 1% (w/w) to about 3.5% (w/w). 6. The liquid pharmaceutical formulation of claim 1, wherein the concentration of tromethamine is from about 50 mM to about 125 mM. 7. The liquid pharmaceutical formulation of claim 1, wherein the liquid pharmaceutical formulation has a pH of between about 7 to about 8.5. 8. The liquid pharmaceutical formulation of claim 1, wherein the liquid pharmaceutical formulation has a pH of between about 7 to about 8. 9. A liquid pharmaceutical formulation comprising: furosemide, or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide is from about 70 mg/mL to about 100 mg/mL; benzyl alcohol, wherein the amount of benzyl alcohol is from about 1% (w/w) to about 3.5% (w/w); and a pharmaceutically acceptable buffer comprising tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of tromethamine is from about 50 mM to about 125 mM; wherein the liquid pharmaceutical formulation has a pH of between about 7 to about 8.5. 10. The liquid pharmaceutical formulation of claim 9, wherein the concentration of furosemide is about 80 mg/mL to 100 mg/mL. 11. The liquid pharmaceutical formulation of claim 9, wherein the concentration of furosemide is about 80 mg/mL. 12. The liquid pharmaceutical formulation of claim 9, wherein the liquid pharmaceutical formulation has a pH of between about 7.5 to about 8.5. 13. The liquid pharmaceutical formulation of claim 10, wherein the liquid pharmaceutical formulation has a pH of between about 7 to about 8. 14. A liquid pharmaceutical formulation comprising: furosemide, or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide is from about 80 mg/mL to about 100 mg/mL; benzyl alcohol, wherein the amount of benzyl alcohol is from about 1% (w/w) to about 3.5% (w/w); and a pharmaceutically acceptable buffer comprising tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of tromethamine is from about 50 mM to about 125 mM; wherein the liquid pharmaceutical formulation has a pH of between about 7 to about 8. 15. The liquid pharmaceutical formulation of claim 14, wherein the concentration of furosemide is about 80 mg/mL. 16. The liquid pharmaceutical formulation of claim 14, wherein the concentration of tromethamine is about 50 mM to 100 mM. 17. The liquid pharmaceutical formulation of claim 15, wherein the concentration of tromethamine is about 50 mM to 100 mM. 18. The liquid pharmaceutical formulation of claim 14, wherein the concentration of tromethamine is about 75 mM to 125 mM. 19. The liquid pharmaceutical formulation of claim 14, further comprising one or more of water, an osmolarity adjuster, and a pH adjuster. 20. The liquid pharmaceutical formulation of claim 15, further comprising one or more of water, an osmolarity adjuster, and a pH adjuster.